Nanexa AB (NANEXA.ST) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Sweden · ISIN SE0007074166

Price
10.32 SEK
Market cap
1.91 bn SEK
P/E (2025)
–
P/S (2025)
52.75
Dividend yield
0.00 %
Net margin
-31.50 %
Return on equity (ROE)
-11.22 %
Return on assets (ROA)
-8.24 %

Nanexa AB financials

Fiscal year20242025
Revenue24.36 m SEK36.15 m SEK
Gross profit46.69 m SEK-8.85 m SEK
Operating income-26.06 m SEK-15.46 m SEK
EBIT-24.55 m SEK-15.46 m SEK
Net income-24.91 m SEK-11.39 m SEK
Diluted EPS – continuing operations-0.18 SEK-0.07 SEK

Full history since 2014, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Nanexa AB

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug from lenalidomide for the treatment of multiple myeloma. The company has collaborations with Novo Nordisk to evaluate PharmaShell technology; and Moderna for the development of pharmaceutical products with active substances. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.